Neurocrine cuts workforce--again

Neurocrine has announced that it is laying off more than half of its workforce following yesterday's approvable letter from the FDA for the sleep drug indiplon. A total of 130 workers at Neurocrine's San Diego location will be let go, leaving the company with 120 employees. The move is part of a restructuring plan designed to save money and focus the company's activities around R&D.

Neurocrine's stock plummeted 45 percent after the FDA said that it would need additional data on its sleep therapy indiplon before it can be approved. The company is preparing a formal meeting request to the FDA to discuss the approvable letter.

- see Neurocrine's release for more

Related Articles:
FDA hands Neurocrine approvable letter. Report
Neurocrine shares sink on news of indiplon delay. Report
FDA wants more data on Neurocrine's indiplon. Report
Deep cuts reported at Neurocrine, Valentis. Report
Struggling to save cash, Neurocrine axes sales force. Report